Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
Journal Reference: RMD Open. 2024;10:e003918 doi: 10.1136/rmdopen-2023-003918
Fleischmann et al. evaluated the long-term efficacy and safety of upadacitinib in rheumatoid arthritis patients with inadequate response or intolerance to bDMARDs over five years. The study demonstrated that upadacitinib 15 mg and 30 mg were effective in maintaining disease control, with >75% of patients achieving CDAI LDA by week 260. The safety profile remained consistent with no new issues identified.
This study looked at patients with RA who had failed to respond to or tolerate one or more bDMARDs and were enrolled in the SELECT-BEYOND phase 3 trial and its LTE. The primary goal was to assess the long-term outcomes of upadacitinib treatment.
Keywords:
